Supplementary Online Content

Walsh SL, Comer SD, Lofwall MR, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. *JAMA Psychiatry*. Published online June 22, 2017.
doi:10.1001/jamapsychiatry.2017.1874

eTable 1. Summary of Plasma Buprenorphine Pharmacokinetic Parameters for CAM2038 q1w 24 mg and CAM2038 q1w 32 mg (Completer Population).
eTable 2. Summary of Plasma Norbuprenorphine Pharmacokinetic Parameters for CAM2038 q1w 24 mg and CAM2038 q1w 32 mg (Completer Population).
eTable 3. Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any CAM2038 q1w Treatment Group and Overall MedDRA System Organ Class and MedDRA Preferred Term (Safety Population).

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Summary of Plasma Buprenorphine Pharmacokinetic Parameters for CAM2038 q1w 24 mg and CAM2038 q1w 32 mg (Completer Population)

		24 mg CAM2038 q1w n=22		32 mg CAM2038 q1w n=24	
		Day 0 to 6	**Day 7 to 13**	**Day 0 to 6**	**Day 7 to 13**
C_{max} (ng/mL)	Geo. Mean	3.64	4.37	4.39	6.01
	Geo. Mean %CV	39.48	35.26	42.74	45.34
	Range	1.76-6.69	1.94-8.57	1.97-11.5	2.83-14.5
C_{trough} (ng/mL)	Geo. Mean	0.822	1.23	0.993	1.47
	Geo. Mean % CV	24.67	22.83	32.19	32.38
	Range	0.472-1.49	0.786-2.07	0.607-2.09	0.939-3.30
C_{av} (ng/mL)	Geo. Mean	1.81	2.29	2.24	3.05
	Geo. Mean % CV	29.78	23.37	30.55	28.81
	Range	1.03-2.68	1.44-3.24	1.21-3.83	2.02-5.27
T_{max} (h)	Median	24.00	24.00	24.00	24.00
$AUC_{0\text{-}168h}$ (h*ng/mL)	Geo. Mean	303.8	385.3	375.7	511.6
	Geo. Mean % CV	29.78	23.37	30.55	28.81

$AUC_{0\text{-}168h}$= area under the plasma concentration-time curve between time 0 and 168 hours after latest injection; AUC_{last}= area under the plasma concentration-time curve from time 0 to last measureable plasma concentration; C_{av}= average plasma concentration during a dosing interval; C_{max}=maximum plasma concentration; C_{trough}= plasma concentration level 7 days after the latest injection; CV=coefficient of variation; Range=Minimum-Maximum; SD=standard deviation; T_{last}= time of last measurable plasma concentration; T_{max}= time to achieve the maximum observed plasma concentration.

eTable 2. Summary of Plasma Norbuprenorphine Pharmacokinetic Parameters for CAM2038 q1w 24 mg and CAM2038 q1w 32 mg (Completer Population)

		24 mg CAM2038 q1w n=22		32 mg CAM2038 q1w n=24	
		Day 0 to 6	**Day 7 to 14**	**Day 0 to 6**	**Day 7 to 14**
C_{max} (ng/mL)	Geo. Mean	0.770	1.10	0.865	1.36
	Geo. Mean % CV	51.43	45.68	51.71	46.77
C_{trough} (ng/mL)	Geo. Mean	0.454	0.703	0.547	0.786
	Geo. Mean % CV	45.01	45.94	43.41	55.92
C_{av} (ng/mL)	Geo. Mean	0.527	0.886	0.605	0.993
	Geo. Mean % CV	49.99	43.56	50.34	45.27
T_{max} (h)	Median	72.00	84.15	72.00	48.03
$AUC_{0\text{-}168h}$ (h*ng/mL)	Geo. Mean	88.61	148.8	101.7	166.9
	Geo. Mean % CV	49.99	43.56	50.34	45.27

$AUC_{0\text{-}168h}$= area under plasma concentration-time curve from time 0 to 168 hours after the latest injection; AUC_{last}= area under the plasma concentration-time curve from time 0 to last measureable plasma concentration; C_{av}= average plasma concentration during a dosing interval; C_{max}=maximum plasma concentration; C_{trough}= plasma concentration level 7 days after the latest injection; CV=coefficient of variation; Range=Minimum-Maximum; SD=standard deviation; T_{last}= time of last measurable plasma concentration; T_{max}= time to achieve the maximum observed plasma concentration.

eTable 3. Treatment-Emergent Adverse Events Occurring in at Least 5% of Patients in Any CAM2038 q1w Treatment Group and Overall by MedDRA System Organ Class and MedDRA Preferred Term (Safety Population)

MedDRA System Organ Class **MedDRA Preferred Term**	**Number (%) of patients**		
	CAM2038 q1w 24mg (N=22)	**CAM2038 q1w 32mg (N=25)**	**All CAM2038 q1w (N=47)**
AEs during Qualification/Baseline HMO Phase			
Patients with at least 1 adverse event	9 (40.9%)	15 (60.0%)	24 (51.1%)
Gastrointestinal disorders	7 (31.8%)	6 (24.0%)	13 (27.7%)
Vomiting	4 (18.2%)	3 (12.0%)	7 (14.9%)
Nausea	2 (9.1%)	3 (12.0%)	5 (10.6%)
Constipation	3 (13.6%)	1 (4.0%)	4 (8.5%)
Nervous system disorders	4 (18.2%)	1 (4.0%)	5 (10.6%)
Headache	4 (18.2%)	0	4 (8.5%)
Investigations	0	4 (16.0%)	4 (8.5%)
Oxygen saturation decreased	0	4 (16.0%)	4 (8.5%)
Cardiac disorders	0	3 (12.0%)	3 (6.4%)
Tachycardia	0	2 (8.0%)	2 (4.3%)
Skin and subcutaneous tissue disorders	0	3 (12.0%)	3 (6.4%)
Pruritus generalized	0	2 (8.0%)	2 (4.3%)
Musculoskeletal and connective tissue disorders	2 (9.1%)	0	2 (4.3%)
Myalgia	2 (9.1%)	0	2 (4.3%)
AEs during CAM2038 Treatment Phase			
Patients with at least 1 adverse event	14 (63.6%)	24 (96.0%)	38 (80.9%)
Gastrointestinal disorders	7 (31.8%)	14 (56.0%)	21 (44.7%)
Constipation	3 (13.6%)	6 (24.0%)	9 (19.1%)
Nausea	1 (4.5%)	3 (12.0%)	4 (8.5%)
Faeces hard	0	2 (8.0%)	2 (4.3%)
General disorders and administration site conditions	6 (27.3%)	10 (40.0%)	16 (34.0%)
Injection site pain	2 (9.1%)	3 (12.0%)	5 (10.6%)
Injection site erythema	2 (9.1%)	2 (8.0%)	4 (8.5%)
Injection site pruritus	1 (4.5%)	2 (8.0%)	3 (6.4%)
Injection site haemorrhage	0	2 (8.0%)	2 (4.3%)
Skin and subcutaneous tissue disorders	4 (18.2%)	5 (20.0%)	9 (19.1%)
Dermatitis contact	1 (4.5%)	2 (8.0%)	3 (6.4%)
Acne	0	2 (8.0%)	2 (4.3%)
Nervous system disorders	4 (18.2%)	2 (8.0%)	6 (12.8%)
Headache	3 (13.6%)	1 (4.0%)	4 (8.5%)

MedDRA System Organ Class MedDRA Preferred Term	Number (%) of patients		
	CAM2038 q1w 24mg (N=22)	CAM2038 q1w 32mg (N=25)	All CAM2038 q1w (N=47)
Cardiac disorders	1 (4.5%)	3 (12.0%)	4 (8.5%)
Ventricular tachycardia	0	2 (8.0%)	2 (4.3%)
Investigations	2 (9.1%)	2 (8.0%)	4 (8.5%)
Musculoskeletal and connective tissue disorders	1 (4.5%)	3 (12.0%)	4 (8.5%)